Press Releases

Emplicure is recruiting new CFO

Erik Magnusson appointed new Chief Financial Officer (CFO) in Emplicure AB.

Emplicure announces today that the company has appointed Erik Magnusson as new CFO, starting January 1 2022. He succeeds Anna-Lena Nicolson, whose contract expires December 31.

"The company is in an exiting phase of growth where Erik's background and experience will be a strong contribution to the development of Emplicure" says Torbjörn W Larsson, CEO at Emplicure.

Erik brings over 25 years of combined experience in financial planning and operations, investor relations, and economic consulting, where he has held financial management positions within i.e. Systembolaget, Aleris, and Coop. He also has background as financial analyst, covering the Nordic medtech and hospital sector at ABG Sundal Collier, among others. Erik will be working part time and will initially work in tandem with Anna-Lena during December to secure a seamless transition.


Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via

This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The informationen was submitted for publication, through the agency of the contact person above, on November 25, 2021 at 11:15 AM CET.

For more information, please contact:

Torbjörn W. Larsson
Phone: +46 (0)70 747 65 99

Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subisidiary, Amplicon AB develops consumer products, with tobacco-free nicotine as the first product. Read more at


Emplicure AB has developed the formulation of Empli03 to be used for GMP manufacturing for the first clinical study. Agreement has been signed with Quotient Sciences, UK, who will be responsible for the manufacturing and will also perform the first pharmacokinetic study.


Emplicure AB announces today that the Nomination Committee for the annual general shareholders meeting (AGM) in April 2022 is formed. The Nomination Committee consists of representatives nominated by the three largest shareholders per the last bank-day in the third quarter, as well as the Chairman of the Board. Emplicure's three largest shareholders, also the founders, have agreed to vote as one, in order to to give preference for more shareholders.


Emplicure AB has received issue notification from the US Patent and Trademark Office that a formal approval of the inhalation platform of pharmaceuticals will be issued on December 21, 2021.


Erik Magnusson appointed new Chief Financial Officer (CFO) in Emplicure AB.


Following this summer's new share issue and subsequent IPO, we are well equipped. The focus of the third quarter has been on shifting up, and driving the development of the company's two main projects; Empli03, our drug candidate for chronic pain, and Amp01, our oral tobacco-free nicotine product in the form of dry, white pouches as a consumer product. Both projects are developed on our own bioceramic and patented technologies and platforms.


Anna-Lena Nicolson, CFO och medlem i ledningsgruppen i Emplicure AB (publ), har idag beslutat att lämna sitt uppdrag. Anna-Lena kommer att kvarstå som CFO till och med den 31 december 2021. Processen med att rekrytera hennes ersättare har inletts.


Emplicure AB (publ) har anställt Anna Franzén som Sr. Manager Clinical Projects för att driva och utveckla bolagets kliniska projekt.



Do you want to know more?

Contact us today.